AETHLON MEDICAL INC (AEMD)
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Medical - Devices
Aethlon Medical, Inc.
Trials need funding. See this company's dilution risk and cash position.
- Not applicableTerminated
Safety Study of the Aethlon Hemopurifier
Affinity plasmapheresis
End Stage Renal Disease, Hepatitis C Infection
NCT02215902Enrollment8StartDec 2014Primary CompletionMar 2017CompletionMar 2017 - Not applicableTerminated
Hemopurifier Plus Pembrolizumab in Head and Neck Cancer
Pembrolizumab 200mg IV
Squamous Cell Carcinoma of the Head and Neck
NCT04453046Enrollment2StartOct 2020Primary CompletionNov 2022CompletionNov 2022 - Not applicableTerminated
Treatment of SARS-CoV-2 Virus Disease (COVID-19) in Humans With Hemopurifier® Device
Hemopurifier
COVID-19
NCT04595903Enrollment1StartJun 2022Primary CompletionNov 2022CompletionNov 2022
| Drug / Therapy | Link | ||
|---|---|---|---|
| Not applicable | Terminated | Affinity plasmapheresis | NCT02215902 |
| Not applicable | Terminated | Pembrolizumab 200mg IV | NCT04453046 |
| Not applicable | Terminated | Hemopurifier | NCT04595903 |